Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

Vaccine

Volumn 25, Issue 19, 2007, Pages 3816-3826

  Siber, George R ^a   Chang, Ih ^b   Baker, Sherryl ^a   Fernsten, Philip ^a   O'Brien, Katherine L ^c   Santosham, Mathuram ^c   Klugman, Keith P ^d,e   Madhi, Shabir A ^e   Paradiso, Peter ^a   Kohberger, Robert ^f  

^a WYETH RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f NONE

Author keywords

Antibody response; Conjugate vaccine; Pneumococcus; Protective antibody level; Protective correlate; Streptococcus pneumoniae; Vaccine; Vaccine licensing; Vaccine regulation

Indexed keywords

BACTERIUM ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL MEMBRANE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT DISEASE; MATHEMATICAL ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL CAPSULES; CALIFORNIA; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; INDIANS, NORTH AMERICAN; INFANT; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 34247120588     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.119     Document Type: Article

References (30)

1. Siber G.R. Methods for estimating serological correlates of protection. Dev Biol Stand 89 (1997) 283-296
2. Robbins J.B., Schneerson R., and Szu S.C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 171 (1995) 1387-1398
3. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21 (2003) 3265-3272
4. WHO, (2005) Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. No. 927.
5. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., et al. Correlates of immune protection induced by live, attenuated, cold adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181 (2000) 1133-1137
6. Black S., Shinefield H., Fireman B., Lewis E., Ray P., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19 (2000) 187-195
7. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 362 (2003) 355-431
8. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., et al. A trial of a 9 valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003) 1341
9. Concepcion N.F., and Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal polysaccharide enzyme linked immunosorbent assay. Clin Diagn Lab Immunol 8 (2001) 266-272
10. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease. Part I. Implications for conjugate vaccine formulation and use. Clin Infect Dis 30 (2000) 100-121
11. Quataert S.A., Kirch C.S., Wiedl L.J., Phipps D.C., Strohmeyer S., et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 2 (1995) 590-597
12. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., et al. Enzyme linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 10 (2003) 514-519
13. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B., et al. Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18 (1999) 757-763
14. Huebner R., Mbelle N., Forrest B., Madore D.V., and Klugman K.P. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J 21 (2002) 1004-1007
15. O'Brien KL, Moisi J, Moulton LH, Madore DV, Eick A, Reid R, et al. Predictors of conjugate pneumococcal vaccine immunogenicity among infants and toddlers in the American Indian PnCRM 7 efficacy trial. J Infect Dis 2007; in press.
16. Cutts F.T., Saman S.M.A., Enwere G., Jaffar S., Levine O.S., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet 356 (2005) 1139
17. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case control study. The Lancet 368 (2006) 1495
18. Henckaerts I., Goldblatt D., Ashton L., and Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol Mar (2006) 356-360
19. Soininen A., Seppala I., Nieminen T., Eskola J., and Kayhty H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17 (1999) 1889-1897
20. Anttila M., Eskola J., Ahman H., and Kayhty. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 17 (1999) 1970-1977
21. Pedersen F.K., Henrichsen J., Sorensen U.S., and Nielsen J.L. Anti-C- carbohydrate antibodies after pneumococcal vaccination. Acta Path Microbiol Immunol Scand Sect C 1982 90 (1982) 353-355
22. Soininen A., van den Dobbelsteen G., Oomen L., and Kayhty H. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?. Clin Diagn Lab Immunol 7 (2000) 468-476
23. Yu J., Briles D.E., Englund J.A., Hollingshead S.K., Glezen W.P., and Nahm M.H. Immunogenic Protein Contaminants in Pneumococcal Vaccines. J Infect Dis 187 (2003) 1019
24. Peeters C., Teubergen-Meekes A.-M., Poolmann J., Zegers B., and Rijkers G. Induction of antipneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates. Med Microbiol Immunol 181 (1992) 35-42
25. Casal J., Jado I., Fenoll A., Perez A., and Torano A. Periodate oxidation of R36A pneumococci greatly enhances production of hybridomas secreting anti protein antibodies. Microb Pathog 24 (1998) 111-116
26. Laferriere C.A., Sood R.K., deMuys J.-M., Michon F., and Jennings H.J. The synthesis of Streptococcus pneumoniae polysaccharide tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine 15 2 (1997) 179-186
27. Madhi S.A., Kuwanda L., Cutland C., Holm A., Kayhty H., et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Ped lnf Dis J 24 5 (2004) 410-416
28. Madhi S.A., Kuwanda L., Saarinen L., Cutland C., Mothupi R., Kayhty H., and Klugman K. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 23 (2005) 5517-5525
29. Jokinen J.T., Ahman H., Kilpi T.M., Makela P.H., and Kayhty M.H. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 190 (2004) 545-550
30. Dagan R., Givon-Lavi N., Fraser D., Lipsitch M., Siber G.R., and Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 192 (2005) 3670-3676